VTVT
Income statement / Annual
Last year (2025), vTv Therapeutics Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, vTv Therapeutics Inc's net income was -$26.97 M.
See vTv Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$1.02 M |
$0.00 |
$2.02 M |
$4.01 M |
$6.41 M |
$2.76 M |
$12.43 M |
$291.00 K |
$634.00 K |
| Cost of Revenue |
$16.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.02 M
|
$15.12 M
|
$23.04 M
|
$39.64 M
|
$45.75 M
|
| Gross Profit |
-$16.00 K
|
$1.02 M
|
$0.00
|
$2.02 M
|
$4.01 M
|
-$4.60 M
|
-$12.36 M
|
-$10.60 M
|
-$39.35 M
|
-$45.11 M
|
| Gross Profit Ratio |
0
|
1
|
0
|
1
|
1
|
-0.72
|
-4.47
|
-0.85
|
-135.22
|
-71.16
|
| Research and Development Expenses |
$17.86 M
|
$11.55 M
|
$13.60 M
|
$12.36 M
|
$13.32 M
|
$11.02 M
|
$15.12 M
|
$23.04 M
|
$39.64 M
|
$45.75 M
|
| General & Administrative Expenses |
$14.95 M
|
$13.65 M
|
$11.91 M
|
$12.20 M
|
$12.34 M
|
$7.25 M
|
$8.54 M
|
$9.22 M
|
$11.33 M
|
$9.91 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.95 M
|
$13.65 M
|
$11.91 M
|
$12.20 M
|
$12.34 M
|
$7.25 M
|
$8.54 M
|
$9.22 M
|
$11.33 M
|
$9.91 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$11.02 M
|
$0.00
|
-$592.00 K
|
-$190.00 K
|
-$22.00 K
|
| Operating Expenses |
$32.81 M
|
$25.20 M
|
$25.50 M
|
$24.56 M
|
$25.67 M
|
$7.25 M
|
$23.66 M
|
$32.26 M
|
$50.97 M
|
$55.65 M
|
| Cost And Expenses |
$32.81 M
|
$25.20 M
|
$25.50 M
|
$24.56 M
|
$25.67 M
|
$18.27 M
|
$23.66 M
|
$32.26 M
|
$50.97 M
|
$55.65 M
|
| Interest Income |
$1.87 M
|
$1.57 M
|
$472.00 K
|
$352.00 K
|
$1.00 K
|
$12.00 K
|
$53.00 K
|
$61.00 K
|
$117.00 K
|
$87.00 K
|
| Interest Expense |
$6.00 K
|
$0.00
|
$13.00 K
|
$15.00 K
|
$12.00 K
|
$692.00 K
|
$1.83 M
|
$3.29 M
|
$3.09 M
|
$398.00 K
|
| Depreciation & Amortization |
$16.00 K
|
$89.00 K
|
$90.00 K
|
$92.00 K
|
$89.00 K
|
$94.00 K
|
$39.00 K
|
$218.00 K
|
$197.00 K
|
$265.00 K
|
| EBITDA |
-$32.79 M |
-$22.52 M |
-$25.86 M |
-$24.77 M |
-$17.52 M |
-$12.02 M |
-$19.97 M |
-$20.14 M |
-$50.56 M |
-$54.69 M |
| EBITDA Ratio |
0
|
-22.14
|
0
|
-12.27
|
-4.37
|
-1.87
|
-7.23
|
-1.62
|
-173.74
|
-86.26
|
| Operating Income Ratio |
0
|
-23.78
|
0
|
-11.17
|
-5.41
|
-1.85
|
-7.56
|
-1.59
|
-174.16
|
-86.78
|
| Total Other Income/Expenses Net |
$1.73 M
|
$1.58 M
|
-$464.00 K
|
-$2.33 M
|
$4.05 M
|
-$950.00 K
|
-$946.00 K
|
-$3.82 M
|
-$3.17 M
|
-$333.00 K
|
| Income Before Tax |
-$31.08 M
|
-$22.61 M
|
-$25.97 M
|
-$24.87 M
|
-$17.62 M
|
-$12.80 M
|
-$21.84 M
|
-$23.65 M
|
-$53.85 M
|
-$55.35 M
|
| Income Before Tax Ratio |
0
|
-22.23
|
0
|
-12.33
|
-4.4
|
-2
|
-7.9
|
-1.9
|
-185.04
|
-87.31
|
| Income Tax Expense |
$0.00
|
$100.00 K
|
$0.00
|
$200.00 K
|
$115.00 K
|
$0.00
|
$100.00 K
|
$200.00 K
|
$800.00 K
|
$0.00
|
| Net Income |
-$26.97 M
|
-$18.46 M
|
-$20.25 M
|
-$19.16 M
|
-$12.99 M
|
-$8.50 M
|
-$21.94 M
|
-$7.91 M
|
-$16.14 M
|
-$16.35 M
|
| Net Income Ratio |
0
|
-18.15
|
0
|
-9.5
|
-3.24
|
-1.33
|
-7.94
|
-0.64
|
-55.48
|
-25.79
|
| EPS |
-3.2 |
-3.2 |
-9.71 |
-9.98 |
-8.29 |
-7.21 |
-28.97 |
-25.42 |
-66.62 |
-68.52 |
| EPS Diluted |
-3.2 |
-3.2 |
-9.71 |
-9.98 |
-8.29 |
-7.21 |
-28.97 |
-25.42 |
-66.62 |
-68.52 |
| Weighted Average Shares Out |
$8.42 M
|
$5.77 M
|
$2.08 M
|
$1.92 M
|
$1.57 M
|
$1.18 M
|
$757.30 K
|
$311.23 K
|
$242.33 K
|
$238.64 K
|
| Weighted Average Shares Out Diluted |
$8.42 M
|
$5.77 M
|
$2.08 M
|
$1.92 M
|
$1.57 M
|
$1.18 M
|
$757.30 K
|
$311.23 K
|
$242.33 K
|
$238.64 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
